233
Views
15
CrossRef citations to date
0
Altmetric
Rapid Communication

The characteristics of VIM-1-producing Klebsiella pneumoniae from South Africa

, , &
Pages 74-78 | Received 08 Jun 2011, Accepted 07 Aug 2011, Published online: 28 Sep 2011
 

Abstract

A study was designed to characterize a carbapenem-resistant Klebsiella pneumoniae (KPSA01) isolated from a patient in Gauteng, South Africa without recent travel outside South Africa. Molecular characterization was done using isoelectric focusing, polymerase chain reaction and sequencing for blaVIM, blaIMP, blaNDM, blaCTX-Ms, blaOXAs, blaTEMs, and blaSHV, plasmid-mediated quinolone resistance determinants, multilocus sequencing typing, plasmid replicon typing, and addiction factors. KPSA01 produced VIM-1 and belonged to the newly described sequence type ST569. The plasmid that harboured blaVIM typed within the narrow host range IncF replicon group, contained the aadA1 gene cassette, and tested positive for the vagCD and ccdAB addiction systems. This is the first report of VIM-1-producing K. pneumoniae outside Europe. It is important that surveillance studies be undertaken in Africa to determine if VIM-1-producing K. pneumoniae are present in significant numbers.

Acknowledgements

This work was supported by research grants from the Calgary Laboratory Services (No. 73-6350).

Declaration of interest: JDDP has previously received research funds from Merck and Astra Zeneca.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.